US 11,972,855 B2
Assessing lesions formed in an ablation procedure
Assaf Govari, Haifa (IL)
Assigned to Biosense Webster (Israel) Ltd., Yokneam (IL)
Filed by BIOSENSE WEBSTER (ISRAEL) LTD., Yokneam (IL)
Filed on Aug. 12, 2021, as Appl. No. 17/400,414.
Prior Publication US 2023/0051977 A1, Feb. 16, 2023
Int. Cl. G16H 20/40 (2018.01); A61B 18/00 (2006.01); A61B 34/00 (2016.01); A61B 90/00 (2016.01); G16H 30/40 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01)
CPC G16H 20/40 (2018.01) [A61B 18/00 (2013.01); A61B 34/25 (2016.02); A61B 90/37 (2016.02); G16H 30/40 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); A61B 2018/00577 (2013.01); A61B 2018/00839 (2013.01); A61B 2018/00904 (2013.01); A61B 2090/364 (2016.02)] 19 Claims
OG exemplary drawing
 
1. A method, comprising:
receiving: (i) three-dimensional (3D) data indicative of a selected 3D section that has been ablated in a patient organ in accordance with a specified contour, the selected 3D section comprising an inner wall of a cylindrically-shaped vessel, and (ii) a dataset, which is indicative of a set of lesions formed during ablation of the selected 3D section;
transforming the selected 3D data into a two-dimensional (2D) map by generating a flattened representation of the selected 3D section; and
checking, on the 2D map, whether the set of lesions covers the specified contour.